Ovagen and the EIC Accelerator: Germ-Free Eggs, Scale Not Shown

Vaccine makers use more than a billion fertilised hens' eggs a year, and Ovagen's EIC report says up to 30% of eggs used in vaccine production carry bacteria inside them. A single contaminated egg can destroy a vaccine batch, at a cost the report puts at up to $480,000. Ovagen, based in Ballina, County Mayo, has worked since 2000 on raising germ-free hens that lay sterile eggs.

In June 2022 the company announced €10 million from the EIC: a €2.5 million grant and €7.5 million in equity. The grant funded Ovavax2, a €3.6 million project from November 2022 to October 2024 to bring germ-free eggs "into mass production". In February 2023 Ovagen told the Irish Examiner it expected to produce up to four million eggs a year by 2026-27, with revenue of €42 million, and to grow from 12 to 75 staff by 2026. In October 2024 it had 17 staff and a new target of 77 by 2029, according to Silicon Republic.

Where Ovagen Stands Now

In October 2024 the Western Development Commission led a €2 million Series A with IRRUS, HBAN, Boole, DeepIE, Spark Crowdfunding and Enterprise Ireland; the company said it had raised more than €21 million since its founding. In August 2026 it announced that the US Department of Agriculture had approved a health certificate for exporting its research eggs to the US, and that Peru had set import requirements for Irish SPF eggs. Neither announcement names a customer or an order.

The Technology: Eggs Without Bacteria

Vaccine makers today buy specific pathogen-free (SPF) eggs. Ovagen instead raises germ-free birds in isolators, reaching three generations of birds by 2013, so that their eggs are free of bacteria. In the EIC report its eggs grew H1N1 flu virus with "yields up to 2-fold higher" than standard suppliers, and an animal vaccine maker confirmed they were "sterile on arrival". In July 2025 the company reported a study with the Pirbright Institute in which its eggs yielded 7,606 doses of yellow fever vaccine per egg, against 422 and 6 in eggs from two SPF suppliers it did not name.

What the EIC Project Promised, and What CORDIS Shows

Ovavax2 was Ovagen's second EIC grant. At the 9 January 2019 cut-off of the EIC SME Instrument Phase 2, part of the Horizon 2020 EIC pilot, the company was selected for OvaVAx, which ran from 1 June 2019 to 30 November 2021 with an EU contribution of €2,356,812.50 towards a total cost of €3,366,875. Its aim was a germ-free flock and pilot-scale production of germ-free eggs for customer evaluation. The final report says the flock and the first germ-free eggs were produced and the eggs were launched commercially at the World Vaccine Conference in Barcelona in October 2021, and Ovagen's timeline lists the first evaluations by vaccine manufacturers as its next milestone.

Ovavax2 set out to produce "the world's first Germ Free egg and bringing it into mass production", to extend testing from influenza to COVID-19, yellow fever and Newcastle disease, and to scale production internationally. The final report gives the H1N1 result and customer feedback, and says material transfer agreements were signed with vaccine makers, contract manufacturers and research organisations to evaluate the eggs. It reports no production volume, no supply contract and no commercial scale-up.

1. Higher yields than SPF eggsShownH1N1 and yellow fever.
2. Customer evaluationsUnder wayMaterial transfer deals.
3. Mass productionNot shownNo volumes reported.
4. 75 staff by 2026Moved to 202917 in October 2024.

The Money

Ovagen's timeline records €1.4 million in early rounds, an €8 million round between 2004 and 2008, €2.36 million from the EU's SME Instrument and the EIC's €10 million package. Whether the €7.5 million EIC equity has been invested is not public; the EIC Fund was not named among the Series A investors. Ovagen does not publish revenue.

What Cannot Be Checked

Why Europe Should Care

The EIC project tied germ-free eggs to pandemic preparedness, and Ovagen calls its product the world's first. The EU has backed it twice, through the SME Instrument and the EIC Accelerator, and it has reported better yields; the commercial scale the EIC project aimed at has not been shown.

The Verdict

Ovagen and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.